ClinicalTrials.gg
Not yet recruitingNCT07854613Updated Oct 15, 2026

De Novo Gastroesophageal Reflux Disease After Sleeve Gastrectomy With and Without Omentopexy

An interventional study of Sleeve Gastrectomy With Omentopexy and Sleeve Gastrectomy Without Omentopexy in Omentopexy, Sleeve Gastrectomy and Gastroesophageal Reflux Disease, sponsored by China-Japan Friendship Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by China-Japan Friendship Hospital · Not applicable, Interventional, and Prevention

How we know

Updated Oct 15, 2026Interventions changedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 56 studies in Gastroesophageal Reflux with a site in China — 16 open to participants now, 17 under way, none of them phase 3. Gastroesophageal Reflux · China.

Planned enrollment
17th of 39
140 · median 90
Started
2026
with 3 others
No phase
24 of 56
11 open now
Primary completion
2027-10
later than 12 of 16 live
Registered
56th of 56
by date
Lead sponsor
2 of 56
China-Japan Friendship Hospital

Among the 56 studies in Gastroesophageal Reflux with a site in China, this one is the 17th largest by planned enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2026, is one of 24 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 56th registered.

Gastroesophageal Reflux

1,216 studies on the registry are indexed under Gastroesophageal Reflux; 204 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

16 of the 56 studies in Gastroesophageal Reflux with a site in China are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 134 Gastroesophageal Reflux studies recruiting now, 58 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Gastroesophageal Reflux with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the effects of sleeve gastrectomy with and without omentopexy on gastroesophageal reflux disease (GERD) in patients with obesity. The main question it aims to answer is:

Does the addition of omentopexy to sleeve gastrectomy reduce the incidence of postoperative GERD compared with sleeve gastrectomy alone, as measured by the proportion of participants with a postoperative GERD-Q score ≥8?

Researchers will compare sleeve gastrectomy with omentopexy to sleeve gastrectomy without omentopexy to determine whether omentopexy reduces the incidence of postoperative GERD.

Participants will:

Undergo sleeve gastrectomy with or without omentopexy according to their randomized treatment assignment.

Complete the GERD-Q questionnaire after surgery to assess gastroesophageal reflux symptoms.

Attend postoperative follow-up visits for assessment of GERD and other clinical outcomes.

03

Conditions studied

  • Omentopexy
  • Sleeve Gastrectomy
  • Gastroesophageal Reflux Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 to 65 years.
  2. (BMI) ≥32.5 kg/m².
  3. Participants who meet the clinical indications for sleeve gastrectomy for the treatment of obesity.
  4. Participants who are willing to undergo sleeve gastrectomy and comply with the study protocol and postoperative follow-up schedule.

Exclusion criteria

Exclusion Criteria:

  1. Preoperative gastroesophageal reflux disease (GERD), defined by any of the following:

    1. GERD-Q score ≥8;
    2. Regular use of high-dose proton pump inhibitors (PPIs) for the management of reflux symptoms;
    3. Patient-reported typical symptoms of gastroesophageal reflux, including heartburn or acid regurgitation.
  2. Hiatal hernia identified by preoperative upper gastrointestinal endoscopy.
  3. Reflux esophagitis classified as Los Angeles grade B, C or D on preoperative upper gastrointestinal endoscopy.
  4. Barrett's esophagus.
  5. Previous bariatric surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Sleeve Gastrectomy With Omentopexy

    Participants will undergo sleeve gastrectomy with omentopexy according to the study protocol.

    Procedure: Sleeve Gastrectomy With Omentopexy

  • Active comparator
    Sleeve Gastrectomy Without Omentopexy

    Participants will undergo sleeve gastrectomy without omentopexy according to the study protocol.

    Procedure: Sleeve Gastrectomy Without Omentopexy

Interventions

  • ProcedureSleeve Gastrectomy With Omentopexy

    Participants assigned to this intervention will undergo sleeve gastrectomy with omentopexy according to the study protocol. Omentopexy will be performed by fixation of the gastric sleeve to the adjacent omental tissue following sleeve gastrectomy.

  • ProcedureSleeve Gastrectomy Without Omentopexy

    Participants assigned to this intervention will undergo sleeve gastrectomy without omentopexy according to the study protocol.

06

What researchers measure

Primary outcomes

  1. Prevalence of de novo postoperative gastroesophageal reflux disease (GERD)

    The proportion of participants with a postoperative GERD-Q score of 8 or higher.

    Time frame: 12 months after surgery

Secondary outcomes

  1. GERD severity assessed by the GERD-HRQL score

    The severity of gastroesophageal reflux disease will be assessed using the GERD-Health Related Quality of Life (GERD-HRQL) questionnaire. The highest score was 75 and the lowest score was 0. Higher scores indicate greater severity of GERD symptoms.

    Time frame: 12 months after surgery

  2. Endoscopic findings of gastroesophageal reflux disease

    Postoperative upper gastrointestinal endoscopy will be performed to assess endoscopic evidence of gastroesophageal reflux disease, including reflux esophagitis and other relevant findings. The presence or absence of endoscopic evidence of gastroesophageal reflux disease will be recorded.

    Time frame: 12 months after surgery

  3. Incidence of hiatal hernia

    The presence of hiatal hernia will be assessed by postoperative upper gastrointestinal endoscopy. The presence and size of hiatal hernia will be recorded based on postoperative upper gastrointestinal endoscopy.

    Time frame: 12 months after surgery

  4. Severity of reflux esophagitis according to the Los Angeles classification

    The severity of reflux esophagitis will be assessed by postoperative upper gastrointestinal endoscopy using the Los Angeles classification (Grades A, B, C, and D).

    Time frame: 12 months after surgery

  5. Postoperative proton pump inhibitor use

    The use of proton pump inhibitors (PPIs) for the management of postoperative GERD will be recorded, including the type of PPI, dosage, frequency of administration, and treatment duration.

    Time frame: 12 months after surgery

07

Study locations

1 site
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Oct 2027, 12 months later.

Of 194 non-industry interventional studies with no phase under Gastroesophageal Reflux, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 68. This study's planned 12 months is below that.

Counting every sponsor, half of 228 studies reached it within 32 months; a quarter within 12 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 2, 2026
StartEst.
Oct 15, 2026
Primary completionEst.
Oct 15, 2027
CompletionEst.
Nov 1, 2027
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Changed Sleeve Gastrectomy→Sleeve Gastrectomy Without Omentopexy. Arm changed Sleeve Gastrectomy→Sleeve Gastrectomy Without Omentopexy
Oct 15, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionGERD severity assessed by the GERD-HRQL score: how it is measured was reworded
Oct 15, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Oct 15, 2026
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionGERD severity assessed by the GERD-HRQL score: how it is measured was reworded
    Interventions Changed Sleeve Gastrectomy→Sleeve Gastrectomy Without Omentopexy. Arm changed Sleeve Gastrectomy→Sleeve Gastrectomy Without Omentopexy
    + 1 other change: verification date
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07854613
Responsible party
Yuntao Nie (Principal Investigator, China-Japan Friendship Hospital) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 15, 2026 (estimated)
Primary completion
Oct 15, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Oct 15, 2026

Study contacts

Yuntao Nie, MD
Contact
nytnyt1231@163.com
18611835860

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion